(PharmaNewsWire.Com, June 23, 2017 ) Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Amgen Inc. Antisense Therapeutics Limited Astellas Pharma Inc. AstraZeneca Plc Axelar AB Boehringer Ingelheim GmbH Eli Lilly and Company F. Hoffmann-La Roche Ltd. Genmab A/S Immunomedics, Inc. Insmed Incorporated Merck & Co., Inc. Merrimack Pharmaceuticals, Inc. Novartis AG PharmAbcine, Inc. Prometheon Pharma, LLC ProteoThera, Inc. Silver Creek Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc. TyrNovo Ltd. XL-protein GmbH
Number of Products under Development for, H2 2016 11 Number of Products under Development by Therapy Area, H2 2016 12 Number of Products under Development by Indication, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Early Stage Products, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Pipeline by Amgen Inc., H2 2016 30 Pipeline by Antisense Therapeutics Limited, H2 2016 31 Pipeline by Astellas Pharma Inc., H2 2016 32 Pipeline by AstraZeneca Plc, H2 2016 33 Pipeline by Axelar AB, H2 2016 34 Pipeline by Boehringer Ingelheim GmbH, H2 2016 35 Pipeline by Eli Lilly and Company, H2 2016 36 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37 Pipeline by Genmab A/S, H2 2016 38 Pipeline by Immunomedics, Inc., H2 2016 39 Pipeline by Insmed Incorporated, H2 2016 40 Pipeline by Merck & Co., Inc., H2 2016 41 Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 42 Pipeline by Novartis AG, H2 2016 43 Pipeline by PharmAbcine, Inc., H2 2016 44 Pipeline by Prometheon Pharma, LLC, H2 2016 45 Pipeline by ProteoThera, Inc., H2 2016 46 Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016 47 Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 48 Pipeline by TyrNovo Ltd., H2 2016 49 Pipeline by XL-protein GmbH, H2 2016 50 Dormant Projects, H2 2016 100 Dormant Projects (Contd..1), H2 2016 101 Dormant Projects (Contd..2), H2 2016 102 Dormant Projects (Contd..3), H2 2016 103 Dormant Projects (Contd..4), H2 2016 104 Dormant Projects (Contd..5), H2 2016 105 Dormant Projects (Contd..6), H2 2016 106 Discontinued Products, H2 2016 107 Discontinued Products (Contd..1), H2 2016 108 Discontinued Products (Contd..2), H2 2016 109 Discontinued Products (Contd..3), H2 2016 110
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: